A draw trial of the effect of Interleukin-1 Receptor Antagonist (anakinra, Kineret®) on the
insulin production in patients with new onset Type 1 diabetes.
Kineret® is already being used in the treatment of patients suffering from rheumatoid
arthritis and preclinical studies are now suggesting that it may also be useful for patients
with Type 1 diabetes. The active substance in Kineret is interleukin-1 receptor antagonist, a
blocker of an immune-signal molecule named interleukin-1.
The trial is a blinded randomised trial, in which the patient is allocated to receive the
active drug (Kineret®) or placebo (saline). The hypothesis is that anti-IL-1 treatment as
add-on therapy to conventional insulin therapy will preserve or enhance beta-cell function.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Steno Diabetes Center Steno Diabetes Center Copenhagen
Collaborators:
Juvenile Diabetes Research Foundation Oeresund Diabetes Academy